ELOCTATE®—the only FVIII powered by Fc Fusion

With Fc Fusion, ELOCTATE stays in circulation 1.5x longer than Advate®1

Mean Factor VIII Profile After a Single Dose (50 IU/kg) in Adults (n=28)2

Mean Factor Chart_revised_ArtboardMean Factor Chart_revised_Artboard
circle-data
  • 16.4-hour terminal half-life for adolescents1
  • 12.7-hour terminal half-life for patients 1 to 5 years old, and 14.9 hours for patients 6 to 11 years old1

Other PK parameters

  • In A-LONG, the PK profile of 28 patients on ELOCTATE obtained at Week 14 was comparable with its PK profile obtained after the first dose1
  • Additionally, FVIII activity reached its maximum level (Cmax) within an hour of ELOCTATE administration3*

PK=pharmacokinetic.

*As demonstrated in a phase 1/2a study of adults with hemophilia A.

Fc Fusion helps ELOCTATE stay in circulation through a natural pathway, and does not accumulate1,4

ELOCTATE contains the Fc region of IgG11

IgG1 allows ELOCTATE to extend its half-life by binding to the neonatal Fc receptor1

IgG1 is a naturally occurring protein that has anti-inflammatory and immunomodulatory properties1,5,6

The molecular mechanism behind the effects achieved by ELOCTATE is not
yet fully understood, including the interaction with cellular Fc receptors that ELOCTATE
may interact with, such as on immune cells6

Poly vector 4,-d-,1-01

Experience Fc Fusion technology in action

With Fc Fusion, ELOCTATE stays in circulation 1.5x longer than Advate®1

Mean Factor VIII Profile After a Single Dose (50 IU/kg) in Adults (n=28)2

Mean Factor Chart_revised_ArtboardMean Factor Chart_revised_Artboard
circle-data
  • 16.4-hour terminal half-life for adolescents1
  • 12.7-hour terminal half-life for patients 1 to 5 years old, and 14.9 hours for patients 6 to 11 years old1
  • In A-LONG, the PK profile of 28 patients on ELOCTATE obtained at Week 14 was comparable with its PK profile obtained after the first dose1

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.

PK=pharmacokinetic.

Fc Fusion helps ELOCTATE stay in circulation through a natural pathway, and does not accumulate1,3

ELOCTATE contains the Fc region of IgG11

IgG1 allows ELOCTATE to extend its half-life by binding to the neonatal Fc receptor1

IgG1 is a naturally occurring protein that has anti-inflammatory and immunomodulatory properties1,4,5

The molecular mechanism behind the effects achieved by ELOCTATE is not
yet fully understood, including the interaction with cellular Fc receptors that ELOCTATE
may interact with, such as on immune cells5

Poly vector 4,-d-,1-01
Sanofi Genzyme logo

This site is intended for United States Residents only.

© 2021 Genzyme Corporation. All rights reserved.

ELOCTATE and Sanofi Genzyme are registered trademarks of Sanofi or an affiliate. All other trademarks are the property of their respective owners.

MAT-US-2003082-v4.0-11/2021 Last Updated: November 2021

Sanofi Genzyme logo